结直肠癌原发与配对转移肿瘤遗传异质性研究进展

doi:10.16288/j.yczz.16-357

遗传 ›› 2017, Vol. 39 ›› Issue (6): 482-490.doi: 10.16288/j.yczz.16-357

结直肠癌原发与配对转移肿瘤遗传异质性研究进展

鲁有望¹(),王昆华^1,^2,³()

1. 昆明理工大学医学院,昆明 650500
2. 昆明医科大学第一附属医院胃肠与疝外科,昆明 650500
3. 云南省消化病研究所,昆明 650500

收稿日期:2016-12-22 修回日期:2017-04-05 出版日期:2017-06-20 发布日期:2017-04-28
作者简介:鲁有望，博士研究生，专业方向：环境医学工程。E-mail: youwanglu@163.com|王昆华，教授，主任医师，博士生导师。研究方向：结直肠基因组学及肿瘤异质性。E-mail: wangkunhua_group@163.com
基金资助:
云南省卫生厅内设机构云南省消化病研究所项目资助课题(2016NS001,2016NS003,2016NS004);云南省教育厅科学研究项目资助课题(2015J054);云南省教育厅科学研究基金重大专项资助课题(ZD2015010)

Research progress on genetic heterogeneity between primary and paired metastatic colorectal cancer

Lu Youwang¹(),Wang Kunhua^1,^2,³()

1. Faculty of Medical , Kunming University of Science and Technology, Kunming 650500, China
2. Department of Gastrointestinal and Hernia surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650500, China
3. Yunnan Institute of Digestive Disease, The First Affiliated Hospital of Kunming Medical University, Kunming 650500, China

Received:2016-12-22 Revised:2017-04-05 Online:2017-06-20 Published:2017-04-28
Supported by:
the Foundation of Yunnan Institute of Digestive Disease(2016NS001,2016NS003,2016NS004);the Scientific Research Project of Yunnan Provincial Bureau of Education(2015J054);The Major project of Yunnan Provincial Bureau of Education(ZD2015010)

摘要/Abstract

摘要：

结直肠癌(colorectal cancer, CRC)是我国常见的致死性肿瘤类型之一。根据体细胞突变谱预测抗EGFR单抗治疗疗效已成为转移性结直肠癌(metastatic colorectal cancer, mCRC)治疗的标准步骤。由于临床上转移样本难以获得,只能采用原发肿瘤替代进行检测。原发和配对转移肿瘤间的遗传异质性会导致原发灶取样无法代表转移灶突变谱。目前CRC原发和配对转移肿瘤间遗传异质性程度仍存在争议。本文就CRC原发和配对转移基因组谱的对比研究进行了综述,并讨论了原发与配对转移肿瘤遗传异质性形成的原因及应对策略。

关键词: 结直肠肿瘤, 遗传异质性, 原发灶, 转移灶

Abstract:

Colorectal cancer (CRC) is one of the leading causes of cancer deaths in China. A standard practice in treating metastatic CRC (mCRC) is to predict benefits of the anti-EGFR monoclonal antibody treatment based on the somatic mutation spectrum. Because metastatic samples are difficult to obtain clinically, primary tumors are normally used instead. However, due to the genetic heterogeneity between primary and paired metastatic tumors, primary site biopsy always underrepresents the mutational landscape of metastatic sites. Currently, the extent of genetic heterogeneity between primary and paired mCRC is still under debate. Here, we review comparative studies of primary and matched mCRC and discuss the underlying causes and potential strategies.

Key words: colorectal cancer, genetic heterogeneity, primary site, metastases site

鲁有望,王昆华. 结直肠癌原发与配对转移肿瘤遗传异质性研究进展[J]. 遗传, 2017, 39(6): 482-490.

Lu Youwang,Wang Kunhua. Research progress on genetic heterogeneity between primary and paired metastatic colorectal cancer[J]. Hereditas(Beijing), 2017, 39(6): 482-490.

参考文献

[1]	Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014.CA Cancer J Clin, 2014, 64(2): 104-117.
[2]	Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis.Cell, 1990, 61(5): 759-767.
[3]	Kennedy EP, Hamilton SR. Genetics of colorectal cancer. Semin Surg Oncol, 1998, 15(2): 126-130.
[4]	Malapelle U, Carlomagno C, de Luca C, Bellevicine C, Troncone G. KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. J Clin Pathol, 2014, 67(1): 1-9.
[5]	Sylvester BE, Vakiani E. Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases. J Gastrointest Oncol, 2015, 6(6): 668-675.
[6]	Miyazaki M, Furuya T, Shiraki A, Sato T, Oga A, Sasaki K. The relationship of DNA ploidy to chromosomal instability in primary human colorectal cancers. Cancer Res, 1999, 59(20): 5283-5285.
[7]	Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut, 2008, 57(7): 941-950.
[8]	Korn WM, Yasutake T, Kuo WL, Warren RS, Collins C, Tomita M, Gray J, Waldman FM. Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer, 1999, 25(2): 82-90.
[9]	Aragane H, Sakakura C, Nakanishi M, Yasuoka R, Fujita Y, Taniguchi H, Hagiwara A, Yamaguchi T, Abe T, Inazawa J, Yamagishi H. Chromosomal aberrations in colorectal cancers and liver metastases analyzed by comparative genomic hybridization. Int J Cancer, 2001, 94(5): 623-629.
[10]	Jiang JK, Chen YJ, Lin CH, Yu IT, Lin JK. Genetic changes and clonality relationship between primary colorectal cancers and their pulmonary metastases-an analysis by comparative genomic hybridization. Genes Chromosomes Cancer, 2005, 43(1): 25-36.
[11]	Vakiani E, Janakiraman M, Shen RL, Sinha R, Zeng ZS, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, Heguy A, Paty P, Chan TA, Saltz LB, Weiser M, Solit DB. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol, 2012, 30(24): 2956-2962.
[12]	Roessler S, Lin GL, Forgues M, Budhu A, Hoover S, Simpson RM, Wu XL, He P, Qin LX, Tang ZY, Ye QH, Wang XW. Integrative genomic and transcriptomic characterization of matched primary and metastatic liver and colorectal carcinoma. Int J Biol Sci, 2015, 11(1): 88-98.
[13]	Al-Mulla F, Keith WN, Pickford IR, Going JJ, Birnie GD. Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer, 1999, 24(4): 306-314.
[14]	Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med, 2008, 358(11): 1160-1174.
[15]	Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 2008, 26(10): 1626-1634.
[16]	Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu DS, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 2008, 359(17): 1757-1765.
[17]	Cejas P, López-Gómez M, Aguayo C, Madero R, de Castro Carpe?o J, Belda-Iniesta C, Barriuso J, Moreno García VM, Larrauri J, López R, Casado E, Gonzalez-Barón M, Feliu J. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One, 2009, 4(12): e8199.
[18]	Knijn N, Mekenkamp LJM, Klomp M, Vink-B?rger ME, Tol J, Teerenstra S, Meijer JWR, Tebar M, Riemersma S, van Krieken JHJM, Punt CJA, Nagtegaal ID. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer, 2011, 104(6): 1020-1026.
[19]	He Q, Xu Q, Wu W, Chen L, Sun WJ, Ying JE. Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer. Onco Targets Ther, 2016, 9: 2329-2335.
[20]	Mostert B, Jiang YQ, Sieuwerts AM, Wang HY, Bolt-de Vries J, Biermann K, Kraan J, Lalmahomed Z, van Galen A, de Weerd V, van der Spoel P, Ramírez-Moreno R, Verhoef C, Ijzermans JNM, Wang YX, Gratama JW, Foekens JA, Sleijfer S, Martens JWM. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer, 2013, 133(1): 130-141.
[21]	Siyar Ekinci A, Demirci U, Cakmak Oksuzoglu B, Ozturk A, Esbah O, Ozatli T, Celik B, Budakoglu B, Turker I, Bal O, Turan N. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma. J Buon, 2015, 20(1): 128-135.
[22]	Lu YW, Liu J, Dong RJ, Wang KH. Concordant analysis of KRAS between primary colorectal cancer and paired metastases: A Meta-Analysis. J Kunming Univ Sci Technol (Nat Sci Ed), 2017, 42(1): 75-84.
[22]	鲁有望, 刘江, 董荣静, 王昆华. 结直肠癌原发与对应转移肿瘤KRAS突变一致性meta分析. 昆明理工大学学报(自然科学版), 2017, 42(1): 75-84.
[23]	Kaneko Y, Kuramochi H, Nakajima G, Inoue Y, Yamamoto M. Degraded DNA may induce discordance of KRAS status between primary colorectal cancer and corresponding liver metastases. Int J Clin Oncol, 2014, 19(1): 113-120.
[24]	Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Shibuya H, Eshima K. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum, 2011, 54(9): 1170-1178.
[25]	Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol, 2009, 27(12): 2091-2096.
[26]	De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol, 2010, 11(8): 753-762.
[27]	Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, Gugenheim J, Becouarn Y, Brunet R, Fonck M, Fran?ois E, Saint-Paul MC, Pedeutour F. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol, 2010, 17(5): 1429-1434.
[28]	Santini D, Spoto C, Loupakis F, Vincenzi B, Silvestris N, Cremolini C, Canestrari E, Graziano F, Galluccio N, Salvatore L, Caraglia M, Zito FA, Colucci G, Falcone A, Tonini G, Ruzzo A. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Ann Oncol, 2010, 21(7): 1565.
[29]	Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, Mavroudis D, Georgoulias V. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol, 2013, 26(2): 302-313.
[30]	Mao C, Wu XY, Yang ZY, Threapleton DE, Yuan JQ, Yu YY, Tang JL. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep, 2015, 5: 8065.
[31]	Vermaat JS, Nijman IJ, Koudijs MJ, Gerritse FL, Scherer SJ, Mokry M, Roessingh WM, Lansu N, de Bruijn E, van Hillegersberg R, van Diest PJ, Cuppen E, Voest EE. Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res, 2012, 18(3): 688-699.
[32]	Tan IB, Malik S, Ramnarayanan K, McPherson JR, Ho DL, Suzuki Y, Ng SB, Yan S, Lim KH, Koh D, Hoe CM, Chan CY, Ten R, Goh BKP, Chung AYF, Tan J, Chan CX, Tay ST, Alexander L, Nagarajan N, Hillmer AM, Tang CL, Chua C, Teh BT, Rozen S, Tan P. High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer. Genome Biol, 2015, 16: 32.
[33]	Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, Vacic V, Emde AK, Cercek A, Yaeger R, Kemeny NE, Saltz LB, Shia JR, D'Angelica MI, Weiser MR, Solit DB, Berger MF. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol, 2014, 15(8): 454.
[34]	Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang ML, Yeatman TJ. Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era. PLoS One, 2015, 10(5): e0126670.
[35]	Xie T, Cho YB, Wang K, Huang DH, Hong HK, Choi YL, Ko YH, Nam DH, Jin J, Yang H, Fernandez J, Deng SB, Rejto PA, Lee WY, Mao M. Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing. Genomics, 2014, 104(4): 234-241.
[36]	Lee SY, Haq F, Kim D, Jun C, Jo HJ, Ahn SM, Lee WS. Comparative genomic analysis of primary and synchronous metastatic colorectal cancers. PLoS One, 2014, 9(3): e90459.
[37]	Kogita A, Yoshioka Y, Sakai K, Togashi Y, Sogabe S, Nakai T, Okuno K, Nishio K. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis. Biochem Biophys Res Commun, 2015, 458(1): 52-56.
[38]	Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med, 2012, 4(127): 127ps110.
[39]	Lu YW, Zhang HF, Liang R, Xie ZR, Luo HY, Zeng YJ, Xu Y, Wang LM, Kong XY, Wang KH. Colorectal cancer genetic heterogeneity delineated by multi-region sequencing. PLoS One, 2016, 11(3): e0152673.
[40]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011, 144(5): 646-674.
[41]	Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology, 2010, 138(6): 2059-2072.
[42]	Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology, 2010, 138(6): 2073-2087.e3.
[43]	Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature, 2013, 501(7467): 338-345.
[44]	Gutenberg A, Gerdes JS, Jung K, Sander B, Gunawan B, Bock HC, Liersch T, Brück W, Rohde V, Füzesi L. High chromosomal instability in brain metastases of colorectal carcinoma. Cancer Genet Cytogenet, 2010, 198(1): 47-51.
[45]	Paget S. The distribution of secondary growths in cancer of the breast. Lancet, 1889, 133(3421): 571-573.
[46]	Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell, 2010, 18(6): 884-901.
[47]	Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang HY, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 2004, 6(1): 17-32.
[48]	Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol, 2006, 1(1): 119-150.
[49]	Bissell MJ, Kenny PA, Radisky DC. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: The role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol, 2005, 70: 343-356.
[50]	Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer, 2009, 9(4): 265-273.
[51]	Hendrix MJC, Seftor EA, Hess AR, Seftor REB. Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nat Rev Cancer, 2003, 3(6): 411-421.
[52]	Radisky DC, Bissell MJ. Matrix metalloproteinase-induced genomic instability. Curr Opin Genet Dev, 2006, 16(1): 45-50.
[53]	Wang C, Li YM, Fang XD. Research progress on liquid biopsy in oncology and its clinical applications. Hereditas (Beijing), 2017, 39(3): 220-231.
[53]	, , . . , 2017, 39(3): 220-231.
[54]	Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem, 2015, 61(1): 112-123.
[55]	Bidard FC, Weigelt B, Reis-Filho JS. Going with the flow: from circulating tumor cells to DNA. Sci Transl Med, 2013, 5(207): 207ps214.
[56]	De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of- principle. Ann Oncol, 2014, 25(9): 1729-1735.
[57]	Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen EM, Nakabayashi M, Lis RT, Lee GSM, Li TT, Chabot MS, Ly A, Taplin ME, Clancy TE, Loda M, Regev A, Meyerson M, Hahn WC, Kantoff PW, Golub TR, Getz G, Boehm JS, Love JC. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol, 2014, 32(5): 479-484.
[58]	Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C, Riethdorf S, Mauermann O, Lafer I, Pristauz G, Lax S, Pantel K, Geigl JB, Speicher MR. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res, 2014, 16(4): 421.
[59]	Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol, 2012, 9(6): 338-350.
[60]	Cassidy JW, Caldas C, Bruna A. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res, 2015, 75(15): 2963-2968.
[61]	Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF, Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K, Davies S, Guintoli T, Lin L, Crowder R, Tao Y, Snider JE, Smith SM, Dukes AF, Sanderson GE, Pohl CS, Delehaunty KD, Fronick CC, Pape KA, Reed JS, Robinson JS, Hodges JS, Schierding W, Dees ND, Shen D, Locke DP, Wiechert ME, Eldred JM, Peck JB, Oberkfell BJ, Lolofie JT, Du FY, Hawkins AE, O'Laughlin MD, Bernard KE, Cunningham M, Elliott G, Mason MD, Thompson DM Jr, Ivanovich JL, Goodfellow PJ, Perou CM, Weinstock GM, Aft R, Watson M, Ley TJ, Wilson RK, Mardis ER. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature, 2010, 464(7291): 999-1005.
[62]	Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierré A, De Thé H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prévost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res, 2012, 18(19): 5314-5328.
[63]	Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res, 2013, 73(17): 5315-5319.
[64]	Zhao XM, Liu ZG, Yu LT, Zhang YJ, Baxter P, Voicu H, Gurusiddappa S, Luan J, Su JM, Leung HCE, Li XN. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol, 2012, 14(5): 574-583.
[65]	Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AMK, Ng K, Ma J, Wienholds E, Dunant C, Pollett A, Gallinger S, McPherson J, Mullighan CG, Shibata D, Dick JE. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science, 2013, 339(6119): 543-548.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

结直肠癌原发与配对转移肿瘤遗传异质性研究进展

Research progress on genetic heterogeneity between primary and paired metastatic colorectal cancer

RichHTML

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

[1]	任新鸾，李联祥，韩淑萍，蔡杰，张宏义，马常义. 家族性支气管哮喘的遗传方式分析[J]. 遗传, 2006, 28(9): 1067-1070.
[2]	钱得胜. 情感性障碍的遗传异质性研究啊[J]. 遗传, 1994, 16(4): 1-4.